查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018511

橫膈肌起搏治療系統市場：按組件、類型、應用和最終用戶分類－2026年至2032年全球市場預測

Diaphragm Pacing Therapy System Market by Component, Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，橫膈膜起搏治療系統市場價值將達到 57.5 億美元，到 2026 年將成長至 61.3 億美元，到 2032 年將達到 97.1 億美元，複合年成長率為 7.77%。

主要市場統計數據
基準年 2025 57.5億美元
預計年份：2026年 61.3億美元
預測年份 2032 97.1億美元
複合年成長率 (%) 7.77%

本節將介紹膈肌起搏療法在現代呼吸照護、臨床決策過程以及不斷發展的醫療設備和照護模式中的作用。

膈肌起搏療法已從一個小眾臨床領域發展成為多方面的治療選擇，其中耐用的植入式技術、先進的刺激模式和不斷擴展的醫療服務模式相互交融。由於電極設計、植入技術和設備可程式設計的改進，臨床醫生越來越重視心律調節器療法，將其作為人工呼吸器和非侵入性療法的替代或補充。同時，設備製造商和臨床研究人員致力於透過整合更聰明的控制演算法，降低手術複雜性、提高患者舒適度並增強與患者自身呼吸運動的同步性。

本文說明了技術、醫療保健服務和證據期望方面的變革性變化，這些變化正在重新定義膈肌起搏系統的開發、實施和報銷。

近年來，膈肌起搏在臨床實踐、技術發展和整體醫療服務模式方面發生了變革性變化。電極材料和植入技術的進步降低了手術的侵入性，並提高了其持久性。同時，脈衝產生器設計和軟體控制的改進擴展了可適應的生理模式範圍。此外，遠端監測、自適應刺激演算法和雲端設備遙測等數位健康功能使臨床醫生能夠制定個人化治療方案，並在患者功能偏離預期模式時及早介入。

我們將評估與關稅相關的供應鏈變化、零件採購重組和生產調整將如何影響設備的可用性、成本和營運連續性。

主要貿易夥伴推出新的關稅措施將對醫療設備的製造、零件採購和供應鏈韌性產生連鎖反應。當關稅影響電極、脈衝產生器或嵌入式軟體模組等零件時，製造商通常會重新評估其供應商名單，認證替代供應商，有時會重新配置產品架構以降低成本風險。這些調整反過來又會影響採購前置作業時間、庫存策略以及與契約製造製造商和分銷合作夥伴的合約關係。

基於全面細分的洞察，揭示哪些類型的組件、醫療設備架構、臨床應用和醫療保健環境對產品採用和優先排序的影響最大。

為了深入了解市場動態，市場區隔有助於明確哪些元件、設備類型、臨床應用和終端使用者環境正在推動技術應用和創新。依組件分類，市場分為三大類：電極、脈衝產生器和軟體，分別突顯硬體可靠性、刺激保真度和嵌入式智慧如何影響臨床療效和整體擁有成本。按類型分類，市場分為兩部分：橫膈膜杯狀電極系統和肌肉內電極系統，重點分析臨床醫生在選擇系統時需要考慮的植入方式、訊號保真度和手術複雜性之間的權衡。

區域性洞察解釋了重點區域的不同管理體制、報銷環境和醫療保健服務模式如何影響商業化和擴散趨勢。

區域背景至關重要，因為全球醫療保健生態系統中的報銷框架、臨床實踐模式和供應鏈結構存在顯著差異。在美洲，監管路徑、已建立的植入中心以及不斷變化的報銷機制，共同決定技術部署的速度和實證醫學的角色。該地區的相關人員通常優先考慮臨床效益和營運影響的證明，這反過來又會影響對真實世界資料收集和上市後監測的投入。

競爭考察和策略公司洞察突顯了產品整合、數位化夥伴關係和製造能力如何定義不斷發展的隔膜起搏生態系統中的領導地位。

競爭格局由成熟的醫療設備製造商、專注於刺激和電極技術的專業創新者、開發封閉回路型控制和分析的軟體公司以及將研究成果轉化為臨床實踐的臨床研究團隊組成。主要企業正投資於整合產品系列組合，這些產品組合融合了穩健的電極、可靠的脈衝產生器以及支援遠端監測和自適應治療調整的軟體平台。隨著相關人員尋求提供支援植入、自適應調整和長期照護的端到端解決方案，醫療設備製造商與數位醫療公司之間的策略合作日益頻繁。

提供高階主管切實可行的建議，以加速臨床證據的創建，保障供應鏈，並建立數位化和服務模式，進而提高採用率和病患療效。

產業領導者應優先採取一系列策略行動，旨在加快產品價值實現速度、增強供應鏈韌性並加深臨床認可。首先，將產品開發與明確的臨床終點（例如改善呼吸功能或減少對外部通氣的依賴）相結合，可確保循證醫學證據能夠推動醫保報銷討論和醫療系統採納。投資於可靠的真實世界數據項目和註冊登記，可以展示長期療效，並為差異化的價值提案奠定基礎。

為了檢驗研究結果及其意義，我們採用了穩健的混合方法研究設計，結合了對臨床醫生的訪談、醫療設備的技術評估、監管和文獻審查以及供應鏈分析。

本調查方法融合了定性和定量方法，旨在對醫療設備、臨床和商業性因素進行全面評估。主要研究包括對植入臨床醫生、器械工程師、採購經理和復健專家進行結構化訪談，以獲取關於手術流程、器械性能和推廣應用障礙的第一手觀點。此外，本研究還查閱了公開的監管文件、同行評審的臨床文獻和臨床試驗註冊資料，以多角度檢驗安全性和有效性結果，並了解不斷變化的終點指標和研究設計。

這篇摘要重點介紹了技術成熟度、證據優先性和協作護理模式如何為更廣泛、更永續部署膈肌起搏系統奠定基礎。

總之，橫膈肌起搏療法正處於一個轉折點，隨著技術成熟、護理模式不斷演進以及對以患者為中心的治療結果日益重視，這為相關人員帶來了新的機會和責任。電極、脈衝產生器和軟體的創新使得更精準的刺激以及與門診和居家照護路徑的無縫銜接成為可能。同時，支付方要求證明其價值的壓力也促使人們更加關注真實世界證據和患者的長期獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 橫膈膜起搏治療系統市場：依組件分類

  • 電極
  • 脈衝發生器
  • 軟體

第9章 橫膈膜起搏治療系統市場：依類型分類

  • 隔膜杯電極系統
  • 肌內電極系統

第10章 橫膈膜起搏治療系統市場：依應用領域分類

  • 呼吸衰竭
    • 急性呼吸衰竭
    • 慢性呼吸衰竭
  • 睡眠呼吸中止症
  • 脫離人工呼吸器

第11章 橫膈膜起搏治療系統市場：依最終使用者分類

  • 門診部
  • 居家照護環境
  • 醫院

第12章 橫膈膜起搏治療系統市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 橫膈膜起搏治療系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 橫膈膜起搏治療系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國橫膈膜起搏治療系統市場

第16章：中國橫膈膜起搏治療系統市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Aetna Inc.
  • Amplitude Surgical
  • Astrotech Corp.
  • Atrotech Oy
  • Avery Biomedical Devices, Inc.
  • Boston Scientific Corporation
  • Diaphragm Direct
  • DYI Sheng Industry Co. Ltd
  • Inspire Medical Systems, Inc.
  • Johnson & Johnson Services, Inc.
  • LivaNova plc
  • Lungpacer Medical Inc
  • Mayo Clinic
  • Medtronic PLC
  • NeuroPace, Inc.
  • Nihon Kohden Corporation
  • Nuvectra Corporation
  • PneumRx, LLC
  • Respicardia, Inc.
  • Splashtop Inc
  • Stimdia Medical Inc.
  • StimWave LLC
  • symplr LLC
  • Synapse Biomedical, Inc.
  • Wellmark
  • ZOLL Medical Corporation
Product Code: MRR-A339DAEFA78A

The Diaphragm Pacing Therapy System Market was valued at USD 5.75 billion in 2025 and is projected to grow to USD 6.13 billion in 2026, with a CAGR of 7.77%, reaching USD 9.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.75 billion
Estimated Year [2026] USD 6.13 billion
Forecast Year [2032] USD 9.71 billion
CAGR (%) 7.77%

Introductory framing that situates diaphragm pacing therapy within modern respiratory care, clinical decision pathways, and evolving device and care-delivery paradigms

Diaphragm pacing therapy has evolved from a specialized clinical niche into a multifaceted therapeutic option that intersects durable implantable technologies, advanced stimulation paradigms, and expanding models of care delivery. Clinicians increasingly consider pacing as an alternative or adjunct to mechanical ventilation and noninvasive therapies, driven by improvements in electrode design, implant techniques, and device programmability. Meanwhile, device makers and clinical researchers have focused on reducing procedural complexity, improving patient comfort, and integrating smarter control algorithms to enhance synchrony with native respiratory efforts.

As a result, decision-makers from hospitals, ambulatory clinics, and home-care providers must weigh clinical evidence, procedural pathways, and long-term patient management considerations when evaluating adoption. Interoperability with respiratory diagnostics and remote-monitoring platforms is becoming a differentiator as clinicians seek to manage chronic respiratory failure and ventilator weaning more proactively. In this context, the synthesis of clinical, regulatory, and commercial drivers provides a practical foundation for stakeholders to assess where diaphragm pacing fits within broader respiratory care strategies.

Explaining the transformative shifts in technology, care delivery, and evidence expectations that are redefining how diaphragm pacing systems are developed, deployed, and reimbursed

Recent years have witnessed transformative shifts that are reshaping the diaphragm pacing landscape across clinical practice, technology development, and care delivery models. Advances in electrode materials and implantation techniques have reduced procedural invasiveness and improved durability, while improvements in pulse generator design and software control have expanded the range of physiological profiles that can be supported. At the same time, digital health capabilities-remote monitoring, adaptive stimulation algorithms, and cloud-enabled device telemetry-are enabling clinicians to personalize therapy and intervene earlier when performance deviates from expected patterns.

Concurrently, payer emphasis on outcomes and value-based care is influencing device adoption pathways, prompting manufacturers to generate evidence focused on functional outcomes, reduced hospitalization days, and improved quality of life. The growth of home-based care and outpatient procedural settings is also altering how devices are delivered, necessitating streamlined training for multidisciplinary teams and clear post-implant care protocols. Taken together, these shifts are encouraging a more patient-centered approach to diaphragm pacing that balances clinical efficacy, ease of use, and long-term management considerations.

Assessing how tariff-driven supply chain shifts, component sourcing realignments, and manufacturing adjustments can influence device availability, costs, and operational continuity

The introduction of new tariff measures by a major trading partner can create a cascade of effects across device manufacturing, component sourcing, and supply chain resilience. When tariffs affect components such as electrodes, pulse generators, or software-embedded modules, manufacturers often reassess supplier footprints, qualify alternative vendors, and sometimes reconfigure product architectures to mitigate cost exposure. These adjustments, in turn, can influence procurement lead times, inventory strategies, and contractual relationships with contract manufacturers and distribution partners.

Beyond direct cost implications, tariffs can drive strategic reorientation, prompting companies to localize certain manufacturing steps, repatriate final assembly, or strengthen regional supply bases to reduce tariff vulnerability. Regulatory filings and device registrations may need updating to reflect manufacturing site changes, which can create additional administrative overhead. For clinical stakeholders and health systems, the indirect consequence is potential variability in lead times and device availability, prompting the need for proactive inventory planning and stronger collaboration with suppliers to ensure continuity of care. In short, tariffs act as a structural pressure that reshapes operational decisions across the product lifecycle rather than an isolated cost element.

Comprehensive segmentation-driven insights that reveal which component types, device architectures, clinical applications, and care settings most strongly influence adoption and product priorities

Insight into market dynamics benefits from segmentation that clarifies which components, device types, clinical applications, and end-user settings drive adoption and innovation. Based on component, the market is studied across Electrodes, Pulse Generator, and Software, which highlights how hardware reliability, stimulation fidelity, and embedded intelligence contribute differently to clinical outcomes and total cost of ownership. Based on type, the market is studied across Diaphragm Cup Electrode System and Intramuscular Electrode System, underscoring the trade-offs between implant approach, signal fidelity, and procedural complexity that clinicians weigh when selecting a system.

Based on application, the market is studied across Respiratory Failure, Sleep Apnea, and Ventilator Weaning, with Respiratory Failure further studied across Acute Respiratory Failure and Chronic Respiratory Failure; this layered view clarifies how acute care pathways differ from chronic disease management and how device performance requirements vary across those settings. Based on end user, the market is studied across Ambulatory Care Facilities, Home Care Settings, and Hospitals, reflecting the diverse operational requirements from peri-procedural support to long-term outpatient monitoring. Together, these segmentation lenses illuminate where technological innovation, reimbursement strategies, and clinical training investments will yield the most meaningful returns for patients and providers.

Regional insights that explain how differing regulatory regimes, reimbursement environments, and care delivery models across key geographies shape commercialization and adoption dynamics

Regional context matters because reimbursement frameworks, clinical practice patterns, and supply chain structures differ substantially across global healthcare ecosystems. In the Americas, regulatory pathways, established implant centers, and evolving reimbursement conversations shape the cadence of adoption and the role of evidence generation. Stakeholders in this region often emphasize proof of clinical benefit and operational impact, which in turn influences investment in real-world data collection and post-market surveillance.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and a mix of public and private payers create variable access pathways; consequently, manufacturers commonly pursue targeted pilot programs and local key opinion leader engagement to demonstrate value in specific national contexts. The Asia-Pacific region presents another dynamic environment characterized by rapid hospital expansion, variable local manufacturing capabilities, and growing interest in home-based respiratory care, prompting vendors to consider regional partnerships and adaptable service models. Across all regions, differences in clinical adoption timelines and care delivery models underscore the importance of region-specific commercialization strategies and collaborative approaches with local clinical and procurement stakeholders.

Competitive and strategic company insights highlighting how product integration, digital partnerships, and manufacturing capabilities determine leadership in the evolving diaphragm pacing ecosystem

The competitive landscape features a mix of established medical device manufacturers, specialized innovators focused on stimulation and electrode technologies, software firms developing closed-loop control and analytics, and clinical research groups translating evidence into clinical practice. Leading firms are investing in integrated product portfolios that combine robust electrodes, reliable pulse generators, and software platforms capable of remote monitoring and adaptive therapy adjustments. Strategic collaborations between device makers and digital health companies are becoming more frequent as stakeholders seek to deliver end-to-end solutions that support implant, titration, and longitudinal care.

In addition, contract manufacturers and component specialists are asserting influence through capabilities in precision manufacturing and regulatory-compliant production. New entrants are differentiating through minimally invasive electrode designs and through the development of algorithms that enable greater personalization. Competitive positioning is increasingly determined by the ability to demonstrate clinical outcomes, streamline implant workflows, and provide comprehensive training and support to multidisciplinary care teams. Intellectual property portfolios, regulatory clearances, and the capacity to scale manufacturing while maintaining quality are the critical vectors that separate leaders from followers in this evolving landscape.

Actionable recommendations for executives to accelerate clinical evidence generation, secure supply chains, and embed digital and service models that improve adoption and patient outcomes

Industry leaders should prioritize a sequence of strategic actions designed to shorten time-to-value, strengthen supply resilience, and deepen clinical acceptance. First, aligning product development with clear clinical endpoints-such as improved respiratory function and reduced dependency on external ventilation-will help ensure that evidence generation supports reimbursement discussions and adoption by health systems. Investing in robust real-world data programs and registries can demonstrate longitudinal outcomes and create the basis for differential value propositions.

Second, supply chain diversification and near-shore manufacturing options should be evaluated to mitigate tariff exposure and reduce lead-time variability. Strengthening partnerships with implanting centers and offering comprehensive training programs will smooth adoption pathways and improve procedural success rates. Third, embedding remote-monitoring capabilities and interoperable software will enhance long-term patient management and create opportunities for value-based contracting. Finally, executives should explore strategic alliances with rehabilitation and home-care providers to deliver coordinated post-implant services, thereby improving patient experience and optimizing total care pathways.

Robust mixed-methods research design combining clinician interviews, technical device assessments, regulatory and literature review, and supply chain mapping to validate findings and implications

The research methodology integrates qualitative and quantitative approaches to produce a comprehensive assessment of device, clinical, and commercial factors. Primary research includes structured interviews with implanting clinicians, device engineers, procurement leaders, and rehabilitation specialists to capture firsthand perspectives on procedural workflows, device performance, and barriers to adoption. These insights are complemented by a review of publicly available regulatory filings, peer-reviewed clinical literature, and clinical trial registries to triangulate safety and efficacy findings as well as to understand evolving endpoints and study designs.

In addition, the methodology incorporates supply chain mapping and supplier interviews to evaluate component sourcing vulnerabilities and manufacturing constraints. Product-level technical assessments examine electrode constructs, pulse generator capabilities, and software feature sets to determine differentiation vectors. Finally, synthesis workshops with clinical and commercial experts were used to validate findings and to translate technical evidence into practical implications for commercialization and care delivery strategies.

Concluding synthesis highlighting how technological maturity, evidence priorities, and collaborative care models set the stage for broader and more sustainable adoption of diaphragm pacing systems

In conclusion, diaphragm pacing therapy stands at an inflection point where technological maturity, evolving care models, and an increased emphasis on patient-centered outcomes converge to create new opportunities and responsibilities for stakeholders. Innovations in electrodes, pulse generators, and software are enabling more precise stimulation and more seamless integration into outpatient and home-based care pathways, while pressure from payers to demonstrate value is sharpening the focus on real-world evidence and long-term patient benefit.

Moving forward, successful adoption will depend on manufacturers' ability to deliver integrated solutions that reduce procedural burden, enable remote management, and provide demonstrable clinical and economic value. Health systems and clinicians should prepare for more collaborative procurement and care models, and they should engage early with manufacturers to shape evidence generation that answers pragmatic clinical questions. Taken together, these developments suggest a pathway toward broader, more sustainable use of diaphragm pacing as part of comprehensive respiratory care strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diaphragm Pacing Therapy System Market, by Component

  • 8.1. Electrodes
  • 8.2. Pulse Generator
  • 8.3. Software

9. Diaphragm Pacing Therapy System Market, by Type

  • 9.1. Diaphragm Cup Electrode System
  • 9.2. Intramuscular Electrode System

10. Diaphragm Pacing Therapy System Market, by Application

  • 10.1. Respiratory Failure
    • 10.1.1. Acute Respiratory Failure
    • 10.1.2. Chronic Respiratory Failure
  • 10.2. Sleep Apnea
  • 10.3. Ventilator Weaning

11. Diaphragm Pacing Therapy System Market, by End User

  • 11.1. Ambulatory Care Facilities
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Diaphragm Pacing Therapy System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Diaphragm Pacing Therapy System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Diaphragm Pacing Therapy System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Diaphragm Pacing Therapy System Market

16. China Diaphragm Pacing Therapy System Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Aetna Inc.
  • 17.7. Amplitude Surgical
  • 17.8. Astrotech Corp.
  • 17.9. Atrotech Oy
  • 17.10. Avery Biomedical Devices, Inc.
  • 17.11. Boston Scientific Corporation
  • 17.12. Diaphragm Direct
  • 17.13. DYI Sheng Industry Co. Ltd
  • 17.14. Inspire Medical Systems, Inc.
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. LivaNova plc
  • 17.17. Lungpacer Medical Inc
  • 17.18. Mayo Clinic
  • 17.19. Medtronic PLC
  • 17.20. NeuroPace, Inc.
  • 17.21. Nihon Kohden Corporation
  • 17.22. Nuvectra Corporation
  • 17.23. PneumRx, LLC
  • 17.24. Respicardia, Inc.
  • 17.25. Splashtop Inc
  • 17.26. Stimdia Medical Inc.
  • 17.27. StimWave LLC
  • 17.28. symplr LLC
  • 17.29. Synapse Biomedical, Inc.
  • 17.30. Wellmark
  • 17.31. ZOLL Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY ELECTRODES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY ELECTRODES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY PULSE GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY PULSE GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY PULSE GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY DIAPHRAGM CUP ELECTRODE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY DIAPHRAGM CUP ELECTRODE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY DIAPHRAGM CUP ELECTRODE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY INTRAMUSCULAR ELECTRODE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY INTRAMUSCULAR ELECTRODE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY INTRAMUSCULAR ELECTRODE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY ACUTE RESPIRATORY FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY ACUTE RESPIRATORY FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY ACUTE RESPIRATORY FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY CHRONIC RESPIRATORY FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY CHRONIC RESPIRATORY FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY CHRONIC RESPIRATORY FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SLEEP APNEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SLEEP APNEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SLEEP APNEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY VENTILATOR WEANING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY VENTILATOR WEANING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY VENTILATOR WEANING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GCC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 104. GCC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. GCC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. G7 DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 122. G7 DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. G7 DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NATO DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 128. NATO DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY RESPIRATORY FAILURE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA DIAPHRAGM PACING THERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)